LPRS3
MCID: LPR021
MIFTS: 67

Leprosy 3 (LPRS3)

Categories: Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Leprosy 3

MalaCards integrated aliases for Leprosy 3:

Name: Leprosy 3 57 29 6
Leprosy 57 12 75 25 59 44 15 17 72
Leprosy, Susceptibility to 57 13
Infection Due to Mycobacterium Leprae 25
Leprosy, Susceptibility to, 3 57
Hansen's Disease 25
Leprosy, Type 3 40
Hansen Disease 25
Lprs3 57

Characteristics:

Orphanet epidemiological data:

59
leprosy
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Worldwide); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
see for a discussion on leprosy susceptibility



Classifications:



External Ids:

Disease Ontology 12 DOID:1024
OMIM 57 246300
ICD9CM 35 030 030.9
MeSH 44 D007918
NCIt 50 C84824
SNOMED-CT 68 81004002
ICD10 33 A30 A30.9
MESH via Orphanet 45 D007918
UMLS via Orphanet 73 C0023343
Orphanet 59 ORPHA548
MedGen 42 C1968668
UMLS 72 C0023343

Summaries for Leprosy 3

Genetics Home Reference : 25 Leprosy, also called Hansen disease, is a disorder known since ancient times. It is caused by bacteria called Mycobacterium leprae and is contagious, which means that it can be passed from person to person. It is usually contracted by breathing airborne droplets from affected individuals' coughs and sneezes, or by coming into contact with their nasal fluids. However, it is not highly transmissible, and approximately 95 percent of individuals who are exposed to Mycobacterium leprae never develop leprosy. The infection can be contracted at any age, and signs and symptoms can take anywhere from several months to 20 years to appear. Mycobacterium leprae Mycobacterium leprae Leprosy affects the skin and the peripheral nerves, which connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, and heat. Most affected individuals have areas of skin damage (cutaneous lesions) and problems with nerve function (peripheral neuropathy); however, the severity and extent of the problems vary widely. Leprosy occurs on a spectrum, in which the most severe form is called multibacillary or lepromatous, and the least severe form is called paucibacillary or tuberculoid. Patterns of signs and symptoms intermediate between these forms are sometimes called borderline forms. Multibacillary leprosy usually involves a large number of cutaneous lesions, including both surface damage and lumps under the skin (nodules). The moist tissues that line body openings such as the eyelids and the inside of the nose and mouth (mucous membranes) can also be affected, which can lead to vision loss, destruction of nasal tissue, or impaired speech. Some affected individuals have damage to internal organs and tissues. The nerve damage that occurs in multibacillary leprosy often results in a lack of sensation in the hands and feet. Repeated injuries that go unnoticed and untreated because of this lack of sensation can lead to reabsorption of affected fingers or toes by the body, resulting in the shortening or loss of these digits. Paucibacillary leprosy typically involves a small number of surface lesions on the skin. There is generally loss of sensation in these areas, but the other signs and symptoms that occur in multibacillary leprosy are less likely to develop in this form of the disorder. In any form of leprosy, episodes called reactions can occur, and can lead to further nerve damage. These episodes can include reversal reactions, which involve pain and swelling of the skin lesions and the nerves in the hands and feet. People with the more severe forms of leprosy can develop a type of reaction called erythema nodosum leprosum (ENL). These episodes involve fever and painful skin nodules. In addition, painful, swollen nerves can occur. ENL can also lead to inflammation of the joints, eyes, and the testicles in men. Leprosy has long been stigmatized because of its infectious nature and the disfigurement it can cause. This stigma can cause social and emotional problems for affected individuals. However, modern treatments can prevent leprosy from getting worse and spreading to other people. While the infection is curable, nerve and tissue damage that occurred before treatment is generally permanent.

MalaCards based summary : Leprosy 3, also known as leprosy, is related to borderline leprosy and buruli ulcer, and has symptoms including skin lesions, sensory loss and motor loss. An important gene associated with Leprosy 3 is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Toll-like Receptor Signaling Pathway. The drugs Dapsone and Antimalarials have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are abnormality of the immune system and cellular

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in superficial peripheral nerves, located in skin, located in mucous membranes of the upper respiratory tract, located in anterior chamber of the eyes, or located in testes, has material basis in Mycobacterium leprae, which is transmitted by aerosol spread from infected nasal secretions to exposed nasal and oral mucosa. The infection has symptom skin lesions, has symptom sensory loss, has symptom motor loss and has symptom eye damage.

Wikipedia : 75 Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacteria Mycobacterium... more...

More information from OMIM: 246300

Related Diseases for Leprosy 3

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 874)
# Related Disease Score Top Affiliating Genes
1 borderline leprosy 35.4 SDHD MLLT1
2 buruli ulcer 33.0 SLC11A1 IL10 IFNG CD40LG
3 peripheral nervous system disease 31.6 TNF SDHD MLLT1
4 immune deficiency disease 31.4 IL2 IL10 CD40LG
5 leishmaniasis 31.3 TNF TLR2 SLC11A1 IL10 IFNG
6 uveitis 31.1 TNF NOD2 IL10 IFNG
7 variola major 31.1 IL2 IFNG
8 sarcoidosis 1 31.1 TNF SLC11A1 NOD2 IL2 IFNG
9 tetanus 31.1 IL2 IL10 IFNG CD40LG
10 cutaneous leishmaniasis 31.0 TNF TLR2 SLC11A1 IL10 IFNG
11 erythema multiforme 31.0 TNF IL2 IFNG
12 sporotrichosis 31.0 IL10 IFNG CD40LG
13 poliomyelitis 30.9 TNF IL10 IFNG
14 smallpox 30.9 TNF IL2 IFNG
15 osteomyelitis 30.9 TNF IL10 IFNG
16 trachoma 30.9 TNF IL10 HSPD1
17 rheumatic disease 30.8 TNF IL10 IFNG CD40LG
18 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.8 IL10 IFNG HSPD1
19 contact dermatitis 30.8 TNF IL10 IFNG
20 arthritis 30.8 TNF NOD2 LACC1 IL10 IFNG
21 multidrug-resistant tuberculosis 30.7 TNF SLC11A1 IL10
22 filariasis 30.7 TNF TLR2 IL2 IL10 IFNG
23 proteasome-associated autoinflammatory syndrome 1 30.7 TNF TLR2 IL10 IFNG
24 human immunodeficiency virus type 1 30.7 TNF IL2 IL10 IFNG CD4
25 mycobacterium tuberculosis 1 30.7 TNF TLR2 SLC11A1 IL10 IFNG HSPE1
26 periodontitis 30.7 TNF TLR2 IL10 IFNG
27 oral tuberculosis 30.6 TNF IL2
28 bone inflammation disease 30.6 TNF IL2 IL10 IFNG
29 autoimmune disease 30.6 TNF IL2 IL10 IFNG HSPD1 CD40LG
30 lyme disease 30.6 TNF TLR2 HSPD1 CD40LG
31 typhoid fever 30.6 TNF SLC11A1 IFNG
32 allergic contact dermatitis 30.5 TNF IL10 IFNG
33 crohn's disease 30.5 TNF SLC11A1 NOD2 LACC1 IL10
34 tuberculoid leprosy 30.5 SDHD MLLT1 IL10 IFNG
35 granulomatous dermatitis 30.5 TNF NOD2
36 acquired immunodeficiency syndrome 30.5 TNF IL2 IL10 IFNG CD4
37 mumps 30.5 TNF IL2 IFNG
38 herpes zoster 30.5 IL2 IL10 IFNG
39 alopecia areata 30.5 TNF IL2 IFNG
40 hepatitis a 30.5 TNF IL10 IFNG
41 endocarditis 30.5 TNF TLR2 IL10 HSPD1
42 demyelinating disease 30.5 TNF IL10 IFNG CD40LG
43 lymphadenitis 30.4 TNF SLC11A1 NOD2 IL10 IFNG
44 extrapulmonary tuberculosis 30.4 TLR2 SLC11A1 IL10 IFNG
45 chagas disease 30.4 TNF TLR2 IL2 IL10 IFNG
46 toxoplasmosis 30.4 TNF TLR2 IL10 IFNG CD40LG
47 visceral leishmaniasis 30.4 TNF TLR2 SLC11A1 IL2 IL10 IFNG
48 melioidosis 30.4 TNF TLR2 IL10 IFNG
49 dermatitis, atopic 30.4 TNF IL2 IL10 IFNG
50 systemic lupus erythematosus 30.4 TNF TLR2 IL2 IL10 IFNG CD40LG

Comorbidity relations with Leprosy 3 via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Leprosy 3:



Diseases related to Leprosy 3

Symptoms & Phenotypes for Leprosy 3

Human phenotypes related to Leprosy 3:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 32 HP:0002715

Symptoms via clinical synopsis from OMIM:

57
Immunology:
susceptibility to infection by mycobacterium leprae causing leprosy

Clinical features from OMIM:

246300

Symptoms:

12
  • skin lesions
  • sensory loss
  • motor loss
  • eye damage

MGI Mouse Phenotypes related to Leprosy 3:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 CD4 CD40LG CD8A HSPD1 IFNG IL10
2 hematopoietic system MP:0005397 10.21 CD4 CD40LG CD8A IFNG IL10 IL2
3 immune system MP:0005387 10.13 CD4 CD40LG CD8A IFNG IL10 IL2
4 endocrine/exocrine gland MP:0005379 10.1 CD4 CD40LG CD8A IFNG IL10 IL2
5 digestive/alimentary MP:0005381 10.03 CD4 IFNG IL10 IL2 NOD2 SLC11A1
6 mortality/aging MP:0010768 10 CD4 CD40LG CD8A HSPD1 IFNG IL10
7 integument MP:0010771 9.86 CD4 CD40LG CD8A IFNG IL10 LRRK2
8 neoplasm MP:0002006 9.56 IFNG IL10 IL2 MLLT1 SDHD SLC11A1
9 nervous system MP:0003631 9.36 CD4 CD40LG CD8A HSPD1 IFNG IL10

Drugs & Therapeutics for Leprosy 3

Drugs for Leprosy 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4 80-08-0 2955
2 Antimalarials Phase 4
3 Vitamins Phase 4
4 Vaccines Phase 4
5 Anti-Bacterial Agents Phase 4
6 Anti-Infective Agents Phase 4
7 Immunosuppressive Agents Phase 4
8 Angiogenesis Inhibitors Phase 4
9 Angiogenesis Modulating Agents Phase 4
10 Immunologic Factors Phase 4
11
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
12
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
13
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
14
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
15
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
16
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
17
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
18
Amitriptyline Approved Phase 3 50-48-6 2160
19
Perphenazine Approved Phase 3 58-39-9 4748
20
Infliximab Approved Phase 3 170277-31-3
21
Rifampicin Approved Phase 2, Phase 3 13292-46-1 5381226 5458213
22
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
23
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
24
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
25
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
26
Norgestimate Approved, Investigational Phase 2, Phase 3 35189-28-7 6540478
27
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
28
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
29
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
30
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3 50-28-2 5757
31
Polyestradiol phosphate Approved Phase 2, Phase 3 28014-46-2
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
33 Tocotrienol Investigational Phase 3 6829-55-6
34 Antifungal Agents Phase 2, Phase 3
35 Hormones Phase 3
36 Cyclosporins Phase 2, Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Calcineurin Inhibitors Phase 2, Phase 3
39 Adjuvants, Immunologic Phase 3
40 Fertility Agents Phase 3
41 Androgens Phase 3
42 Tocotrienols Phase 3
43 Tocopherols Phase 3
44 Gastrointestinal Agents Phase 3
45 Dermatologic Agents Phase 3
46 Antirheumatic Agents Phase 3
47 Neurotransmitter Agents Phase 3
48 Antidepressive Agents Phase 3
49 Narcotics Phase 3
50 Tranquilizing Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
4 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
5 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Recruiting NCT03519568 Phase 4
6 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
7 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
8 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
9 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
10 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
11 A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
12 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
13 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
14 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
15 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
16 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
17 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Active, not recruiting NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
18 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
19 To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus. Unknown status NCT02023411 Phase 2 Teriparatide
20 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
21 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00162760 Phase 2 Thalidomide
22 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
23 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
24 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
25 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
26 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
27 Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia Patients of Pakistan Recruiting NCT03651102 Phase 2 Thalidomide Oral Product
28 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
29 Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease Recruiting NCT02968212 Phase 2 Clofazimine
30 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
31 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
32 A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. Terminated NCT00469703 Phase 2 Thalidomide
33 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
34 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
35 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
36 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
37 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
38 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
39 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
40 A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG. Completed NCT00654316 Phase 1
41 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
42 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis. Completed NCT00456183 Phase 1
43 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV Completed NCT00395720 Phase 1
44 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
45 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
46 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
47 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
48 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717
49 Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting Completed NCT02484469
50 Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis Completed NCT02085317 acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis

Search NIH Clinical Center for Leprosy 3

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Thalidomide

Cochrane evidence based reviews: leprosy

Genetic Tests for Leprosy 3

Genetic tests related to Leprosy 3:

# Genetic test Affiliating Genes
1 Leprosy 3 29 TLR2

Anatomical Context for Leprosy 3

MalaCards organs/tissues related to Leprosy 3:

41
Skin, Testes, T Cells, Eye, Bone, Liver, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Leprosy 3:

19
Skin, Superficial Peripheral Nerves, Mucous Membranes Of The Upper Respiratory Tract, Anterior Chamber Of The Eyes, Testes

Publications for Leprosy 3

Articles related to Leprosy 3:

(show top 50) (show all 19866)
# Title Authors PMID Year
1
No involvement of non-synonymous TLR2 polymorphisms in Japanese leprosy patients. 38 8 71
19111445 2009
2
TLR2 Arg677Trp polymorphism in leprosy: revisited. 38 8 71
15726416 2005
3
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. 38 8 71
12646604 2003
4
Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. 38 71
19456232 2009
5
Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. 38 8
18177245 2008
6
Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. 38 71
11476982 2001
7
The polymorphism P315L of human toll-like receptor 1 impairs innate immune sensing of microbial cell wall components. 71
17475868 2007
8
A family of human receptors structurally related to Drosophila Toll. 8
9435236 1998
9
Platelet-rich plasma and its utility in medical dermatology: A systematic review. 38
31009668 2019
10
Revisiting the tuberculosis and leprosy cross-immunity hypothesis: Expanding the dialogue between immunology and paleopathology. 38
31185376 2019
11
Socioeconomic determinants of leprosy new case detection in the 100 Million Brazilian Cohort: a population-based linkage study. 38
31331811 2019
12
Serum Anti-PGL-1 IgG, IgM, and IgA in a 3-Year Follow-up Study of 4-15-Year-old Leprosy Contacts. 38
31220042 2019
13
Experimental validation of biocompatible nanostructured lipid carriers of sophorolipid: Optimization, characterization and in-vitro evaluation. 38
31254745 2019
14
Mycobacterium leprae's evolution and environmental adaptation. 38
31152726 2019
15
Quantifying risk factors to guide progress towards leprosy elimination. 38
31331812 2019
16
Ichthyosiform sarcoidosis: a mimic of leprosy? 38
30593683 2019
17
Does social vulnerability define the risk of leprosy in an endemic region? A time trend analysis in leprosy-endemic area. 38
31347206 2019
18
Risk Factors for Physical Disability in Patients With Leprosy: A Systematic Review and Meta-analysis. 38
31389998 2019
19
Verrucous carcinoma on the foot arising in a chronic neuropathic ulcer of leprosy. 38
30841011 2019
20
Trend analysis of leprosy indicators in a hyperendemic Brazilian state, 2001-2015. 38
31390430 2019
21
Association of non-tuberculous mycobacteria with Mycobacterium leprae in environment of leprosy endemic regions in India. 38
30445113 2019
22
WITHDRAWN: Interventions for skin changes caused by nerve damage in leprosy. 38
31425616 2019
23
Leprosy in Far North Queensland: almost gone, but not to be forgotten. 38
31231806 2019
24
Oro-facial manifestations in lepromatous leprosy patients in Central India: clinical findings from a cross-sectional study. 38
31435822 2019
25
Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells. 38
31371410 2019
26
Spatial clustering, social vulnerability and risk of leprosy in an endemic area in Northeast Brazil: an ecological study. 38
30903718 2019
27
Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field. 38
31422044 2019
28
Archival, paleopathological and aDNA-based techniques in leprosy research and the case of Father Petrus Donders at the Leprosarium 'Batavia', Suriname. 38
31430635 2019
29
Survival of Mycobacterium leprae and association with Acanthamoeba from environmental samples in the inhabitant areas of active leprosy cases: A cross sectional study from endemic pockets of Purulia, West Bengal. 38
30658215 2019
30
Insights into Computational Drug Repurposing for Neurodegenerative Disease. 38
31326236 2019
31
Invasion of human microvascular endothelial cells by Mycobacterium leprae through Mce1A protein. 38
31432529 2019
32
Increased bone marrow-specific adipogenesis by clofazimine causes impaired fracture healing, osteopenia and osteonecrosis without extra-skeletal effects in rats. 38
31393584 2019
33
The Continuing Relevance of Leprosy. 38
31389975 2019
34
Histioid Leprosy a Rare Variant: First Report in Ecuador. 38
31395272 2019
35
Late-onset ulnar neuritis following treatment of lepromatous leprosy infection. 38
31425515 2019
36
Comment on 'Ichthyosiform sarcoidosis: a mimic of leprosy?' 38
30822369 2019
37
Ichthyosiform sarcoidosis: a mimic of leprosy? Reply from authors. 38
30903704 2019
38
Leprosy after interleukin 6 inhibitor therapy in a patient with rheumatoid arthritis. 38
31250825 2019
39
Image Gallery: Clofazimine-induced hyperpigmentation of leprosy plaques. 38
31281972 2019
40
Intrapartum leprosy. 38
31384212 2019
41
Nutritional aspects of people affected by leprosy, between 2001 and 2014, in semi-arid Brazilian municipalities. 38
31340262 2019
42
Physical disabilities due to leprosy in Alagoas State, Northeast Brazil: a temporal and spatial modeling. 38
31340360 2019
43
Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease. 38
31308240 2019
44
A rare cause of ulnar nerve entrapment at the elbow in a patient with leprosy. 38
31372358 2019
45
Immunological biomarkers of subclinical infection in household contacts of leprosy patients. 38
31109749 2019
46
Interventions for ulceration and other skin changes caused by nerve damage in leprosy. 38
31425632 2019
47
Neurosurgical treatment of leprosy neuropathy in a low-incidence, European country. 38
30903414 2019
48
Leprosy in French Guiana 2007-2014: a re-emerging public health problem. 38
31286485 2019
49
The cell fate regulator NUPR1 is induced by Mycobacterium leprae via type I interferon in human leprosy. 38
31344041 2019
50
Emergence and transmission of drug/multidrug-resistant Mycobacterium leprae in a former leprosy colony in the Brazilian Amazon. 38
31260522 2019

Variations for Leprosy 3

ClinVar genetic disease variations for Leprosy 3:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TLR2 NM_003264.5(TLR2): c.2029C> T (p.Arg677Trp) single nucleotide variant risk factor rs121917864 4:154626088-154626088 4:153704936-153704936

Copy number variations for Leprosy 3 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 255081 9 72339785 73251640 Duplication TRPM3 Leprosy

Expression for Leprosy 3

Search GEO for disease gene expression data for Leprosy 3.

Pathways for Leprosy 3

Pathways related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 TNF NOD2 IL2 IL10 IFNG CD40LG
2
Show member pathways
13.08 TNF TLR2 NOD2 IL2 IL10 IFNG
3
Show member pathways
12.72 TNF LRRK2 IL2 IL10 IFNG HSPD1
4
Show member pathways
12.61 TNF IL2 IL10 IFNG CD40LG CD4
5
Show member pathways
12.58 TNF TLR2 NOD2 IL2 IL10 IFNG
6
Show member pathways
12.56 TNF IL2 IL10 IFNG CD4
7 12.52 TNF TLR2 IL2 IL10 IFNG CD8A
8
Show member pathways
12.52 TNF IL2 IL10 IFNG CD8A CD40LG
9
Show member pathways
12.23 TNF TLR2 IL10 IFNG CD40LG
10 12.21 TNF TLR2 NOD2 IL10 IFNG HSPD1
11 12.15 TNF MBD1 IL10 HSPD1
12
Show member pathways
12.02 TNF TLR2 IFNG HSPD1
13
Show member pathways
12 TNF TLR2 IL2 IL10 IFNG CD4
14
Show member pathways
11.96 IL2 IFNG CD8A CD4
15 11.89 TNF TLR2 IL10 IFNG
16 11.84 TNF CD8A CD4
17 11.82 TNF TLR2 IFNG
18 11.8 TNF IL2 IL10 IFNG CD8A CD4
19
Show member pathways
11.75 TNF IL2 IFNG CD40LG
20 11.7 TNF IL2 IL10 IFNG
21
Show member pathways
11.64 TNF IL2 IFNG CD40LG
22
Show member pathways
11.61 TNF IL2 IFNG CD8A
23 11.58 TNF TLR2 HSPD1
24 11.56 IL10 CD40LG CD4
25 11.54 TNF IL2 IL10 IFNG CD8A CD4
26 11.53 TNF IL2 IFNG
27 11.5 TNF TLR2 IFNG
28 11.5 TNF IL2 IFNG
29 11.47 IL2 IL10 IFNG CD4
30 11.46 TNF TLR2 IL10 IFNG CD40LG
31 11.37 CD8A CD40LG CD4
32 11.37 TNF IL10 IFNG
33 11.31 IL2 IFNG CD40LG
34 11.22 IL2 IFNG CD4
35 11.19 TNF IL2 IL10 CD40LG
36 11.18 IL2 IL10 IFNG
37 10.97 TNF IL2 IL10 IFNG CD8A CD4
38 10.82 TNF IL2 IL10 IFNG CD4

GO Terms for Leprosy 3

Cellular components related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 TNF TLR2 NOD2 HSPD1 CD40LG CD4
2 membrane raft GO:0045121 8.92 TNF TLR2 LRRK2 CD4

Biological processes related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 TNF TLR2 SLC11A1 IL10 CD40LG
2 cytokine-mediated signaling pathway GO:0019221 9.97 TNF IL2 IL10 CD4
3 defense response to bacterium GO:0042742 9.94 TNF SLC11A1 NOD2 IL10
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF TLR2 NOD2 CD40LG
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.83 TNF HSPE1 HSPD1
6 cellular response to organic cyclic compound GO:0071407 9.81 TNF NOD2 LRRK2
7 positive regulation of protein phosphorylation GO:0001934 9.8 TNF LRRK2 IL2 IFNG CD4
8 positive regulation of MAP kinase activity GO:0043406 9.79 TNF NOD2 LRRK2
9 positive regulation of T cell proliferation GO:0042102 9.79 IL2 CD40LG CD4
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.77 TNF TLR2 NOD2
11 response to lipopolysaccharide GO:0032496 9.75 TLR2 SLC11A1 IL10
12 T cell activation GO:0042110 9.74 HSPD1 CD8A CD4
13 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 TNF IL10
14 negative regulation of growth of symbiont in host GO:0044130 9.67 TNF IL10
15 B cell proliferation GO:0042100 9.67 IL10 HSPD1 CD40LG
16 response to organic substance GO:0010033 9.66 TNF IL10
17 positive regulation of interleukin-17 production GO:0032740 9.65 NOD2 IL2
18 response to molecule of bacterial origin GO:0002237 9.65 TLR2 IL10
19 positive regulation of interleukin-8 production GO:0032757 9.65 TNF TLR2 NOD2
20 positive regulation of programmed cell death GO:0043068 9.64 TNF LRRK2
21 response to glucocorticoid GO:0051384 9.63 TNF IL10
22 endothelial cell apoptotic process GO:0072577 9.62 TNF IL10
23 positive regulation of interleukin-6 production GO:0032755 9.62 TNF TLR2 NOD2 HSPD1
24 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.61 SLC11A1 NOD2
25 positive regulation of inflammatory response GO:0050729 9.61 TNF TLR2 IL2
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.6 TNF IL10
27 regulation of immunoglobulin secretion GO:0051023 9.56 TNF CD40LG
28 positive regulation of interferon-gamma production GO:0032729 9.56 TNF SLC11A1 IL2 HSPD1
29 receptor biosynthetic process GO:0032800 9.54 TNF IL10
30 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.54 TLR2 NOD2 LRRK2
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 TNF IFNG
32 cytokine secretion involved in immune response GO:0002374 9.51 TLR2 NOD2
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 TNF IFNG
34 positive regulation of interleukin-12 production GO:0032735 9.46 TLR2 IFNG HSPD1 CD40LG
35 positive regulation of tumor necrosis factor secretion GO:1904469 9.36 LRRK2
36 immune response GO:0006955 9.28 TNF TLR2 SLC11A1 IL2 IL10 IFNG
37 positive regulation of interleukin-10 production GO:0032733 9.26 TLR2 NOD2 HSPD1 CD40LG

Molecular functions related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chaperone binding GO:0051087 9.13 PACRG HSPE1 HSPD1
2 cytokine activity GO:0005125 9.02 TNF IL2 IL10 IFNG CD40LG

Sources for Leprosy 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....